FDA: Long-term clopidogrel doesn’t affect risk of death

The incidence of cancer adverse events was 4.2% for the long-term clopidogrel-plus-aspirin arm and 4.0% for the comparator arm (MH RD of 0.19%; 95% CI, -0.2%-0.59%).

The FDA conducted the second meta-analysis to assess cancer-related death. The analysis included 5 trials (40,855 patients).

The incidence of cancer death was 0.9% for the long-term clopidogrel-plus-aspirin arm and 1.1% for the comparator arm (MH RD of -0.14%; 95% CI, -0.33%-0.06%).

The FDA said that, taken together, the results of this review do not suggest an increased risk of cancer adverse events, cancer-related death, or all-cause mortality with long-term clopidogrel therapy.

More details can be found in the FDA’s Drug Safety Communication on this topic.